NDA 207946 · Janssen Pharms
Invega Hafyera
Paliperidone Palmitate · Intramuscular
Priority reviewLast checked: Nov 20, 2026Latest source record: Jan 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
May 18, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
144
50 Phase 3, 2 recruiting
FAERS reports
8,538
5,139 serious, 599 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA HAFYERA is not approved for use in patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA HAFYERA is not approved for use in patients with dementia-related psychosis. ( 5.1 )
What it is approved for
From the label in effect Feb 18, 2025.
INVEGA HAFYERA, an every-six-month injection, is indicated for the treatment of schizophrenia in adults after they have been adequately treated with: A once-a-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA SUSTENNA) for at least four months, or An every-three-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA TRINZA) for at least one three-month cycle. INVEGA HAFYERA, an every-six-month injection, is an atypical antipsychotic indicated for the treatment of schizophrenia in adults after they have been adequately treated with: A once-a-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA SUSTENNA) for at least four months or An every-three-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA TRINZA) for at least one three-month cycle. ( 1 )
Mechanism: Paliperidone palmitate is hydrolyzed to paliperidone [see Clinical Pharmacology (12.3) ] . Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone is unclear. However, its efficacy in the treatment of schizophrenia could be mediated through a combination of central dopamine D 2 and serotonin 5HT 2A receptor antagonism.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 30, 2021 Supplement 10 · Efficacy LetterLabel
- May 18, 2015 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Summary ReviewLetterLabel
6 products under this application
- INVEGA HAFYERA · PALIPERIDONE PALMITATE 1.560GM/5ML (312MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
- INVEGA TRINZA · PALIPERIDONE PALMITATE 819MG/2.625ML (312MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
- INVEGA TRINZA · PALIPERIDONE PALMITATE 410MG/1.315ML (311.79MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
- INVEGA HAFYERA · PALIPERIDONE PALMITATE 1.092GM/3.5ML (312MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
- INVEGA TRINZA · PALIPERIDONE PALMITATE 546MG/1.75ML (312MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
- INVEGA TRINZA · PALIPERIDONE PALMITATE 273MG/0.875ML (273MG/0.875ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Paliperidone Palmitate" as an intervention, any sponsor and status, largest first.
- An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With SchizophreniaPivotal-lookingCompleted
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
NCT00460512 · 1,814 participants · Start Apr 25, 2007 · Primary completion Jan 22, 2009
Drug: Paliperidone ER · For: Schizophrenia
Sites: Antwerp, Belgium; Bertrix, Belgium; Dave, Belgium · 231 sites in all
- Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With SchizophreniaPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01515423 · 1,429 participants · Start May 2012 · Primary completion Feb 2015
Drug: PP3M 175 mg eq.; PP3M 263 mg eq. and 7 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Glendale, California; Long Beach, California · 174 sites in all
- Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With SchizophreniaPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00589914 · 1,221 participants · Start Mar 2007 · Primary completion Jun 2009
Drug: RISPERDAL CONSTA; Paliperidone palmitate · For: Schizophrenia
Sites: Birmingham, Alabama; Little Rock, Arkansas; Cerritos, California · 82 sites in all
- Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With SchizophreniaPivotal-lookingCompleted
Janssen PharmaceuticaJohnson & Johnson (Janssen) (JNJ)
NCT01662648 · 1,117 participants · Start Jun 2007 · Primary completion Apr 2008
Drug: Paliperidone ER · For: Schizophrenia
- Paliperidone Palmitate Flexible Dosing in SchizophreniaPivotal-lookingCompleted
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
NCT01281527 · 1,044 participants · Start Nov 2010 · Primary completion Nov 2012
Drug: Paliperidone Palmitate · For: Schizophrenia
Sites: Salzburg, Austria; Brussels, Belgium; Dave, Belgium · 127 sites in all
- A Study of Paliperidone Palmitate 6-Month FormulationPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03345342 · 841 participants · Start Nov 20, 2017 · Primary completion May 8, 2020
Drug: PP6M; PP3M 350 mg eq. and 2 more · For: Schizophrenia
Sites: Rogers, Arkansas; Anaheim, California; Costa Mesa, California · 138 sites in all
- Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral AntipsychoticsPivotal-lookingCompleted
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
NCT01081769 · 769 participants · Start Feb 2010 · Primary completion Feb 2013
Drug: paliperidone palmitate injection; oral antipsychotics · For: Schizophrenia
Sites: Vienna, Austria; Bertrix, Belgium; Ghent, Belgium · 94 sites in all
- A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I DisorderPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00490971 · 768 participants · Start May 2006 · Primary completion Apr 2010
Drug: Olanzapine; Paliperidone ER and 1 more · For: Bipolar Disorder
Sites: Scottsdale, Arizona; Riverside, California; San Diego, California · 78 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective842
- off label use790
- hospitalisation646
- schizophrenia556
- condition aggravated508
- product dose omission issue407
- therapeutic response decreased342
- death319
- psychotic disorder317
- weight increased307
- suicide attempt264
- dyskinesia260
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 7 |
| 2011 | 15 |
| 2012 | 76 |
| 2013 | 74 |
| 2014 | 49 |
| 2015 | 126 |
| 2016 | 445 |
| 2017 | 769 |
| 2018 | 609 |
| 2019 | 609 |
| 2020 | 504 |
| 2021 | 592 |
| 2022 | 1,262 |
| 2023 | 1,107 |
| 2024 | 962 |
| 2025 | 786 |
| 2026 | 537 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Invega Hafyera (Paliperidone Palmitate)
2024 spending
$109M
Beneficiaries
3,448
5,856 claims
Per beneficiary
$31,737
$4,143.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $2,953,004 |
| 2022 | $40,918,618 |
| 2023 | $79,118,112 |
| 2024 | $109,428,680 |
Part D: Invega Trinza (Paliperidone Palmitate)
2024 spending
$550M
Beneficiaries
19,150
63,911 claims
Per beneficiary
$28,710
$3,985.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $416,510,098 |
| 2021 | $438,928,871 |
| 2022 | $476,700,024 |
| 2023 | $529,817,416 |
| 2024 | $549,801,574 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review.
Pacchiarotti I, Tiihonen J, Kotzalidis GD, et al. · Eur Neuropsychopharmacol 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Achieving better outcomes for schizophrenia patients in Hong Kong: Strategies for improving treatment adherence.
Lo WA, Ki-Yan Mak D, Ming-Cheuk Wong M, et al. · CNS Neurosci Ther 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
Lin D, Thompson-Leduc P, Ghelerter I, et al. · CNS Drugs 2021 · Comparative Study, Meta-Analysis
- Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Augusto M, Greene M, Touya M, et al. · J Comp Eff Res 2018 · Clinical Trial, Phase III, Comparative Study
- A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Najarian D, Sanga P, Wang S, et al. · Int J Neuropsychopharmacol 2022 · Multicenter Study, Randomized Controlled Trial
- Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis.
Li Q, Li X, Ye C, et al. · CNS Drugs 2023 · Meta-Analysis, Systematic Review
Sponsor: Johnson & Johnson (Janssen) · Also marketed as Invega Trinza
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.